Fibrillex & Alzhemed

At Annual General Meeting of Shareholders Neurochem highlights important developments for key product candidates: "'We have achieved major milestones for Fibrillex(TM) and Alzhemed(TM) in the past year and fiscal 2006 promises to be as exciting,' said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO. 'We continue to strengthen our Company by reaching important stages in the development of our key product candidates. The filing by the FDA of the NDA for Fibrillex(TM), along with the priority review designation that we have recently announced is a major accomplishment for our Company. With the completion of the North American Phase III clinical trials for Alzhemed(TM) scheduled for January 2007, we are taking important strides towards the possibility of introducing our innovative product candidates to patients around the world, pending approval by the regulatory agencies.'"